SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Holdings Lowered by Sei Investments Co.

Sei Investments Co. lowered its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 9.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,309 shares of the company’s stock after selling 2,859 shares during the quarter. Sei Investments Co.’s holdings in SpringWorks Therapeutics were worth $1,023,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. AlphaQuest LLC boosted its holdings in shares of SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after buying an additional 414 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of SpringWorks Therapeutics during the fourth quarter valued at approximately $45,000. KBC Group NV lifted its position in shares of SpringWorks Therapeutics by 59.1% in the 4th quarter. KBC Group NV now owns 2,634 shares of the company’s stock valued at $95,000 after acquiring an additional 978 shares in the last quarter. US Bancorp DE boosted its stake in SpringWorks Therapeutics by 56.0% in the 4th quarter. US Bancorp DE now owns 4,336 shares of the company’s stock worth $157,000 after purchasing an additional 1,556 shares during the period. Finally, Park Avenue Securities LLC acquired a new position in SpringWorks Therapeutics in the 4th quarter worth approximately $203,000.

Insider Buying and Selling

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.36, for a total value of $1,617,210.00. Following the completion of the sale, the insider now directly owns 50,762 shares of the company’s stock, valued at $2,759,422.32. The trade was a 36.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Bhavesh Ashar sold 1,016 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the transaction, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. This represents a 1.61 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 440,766 shares of company stock worth $24,402,956. Insiders own 7.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SWTX. Evercore ISI boosted their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Guggenheim dropped their price target on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Finally, Wedbush reaffirmed an “outperform” rating and set a $81.00 target price on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics has a consensus rating of “Buy” and an average price target of $73.20.

SpringWorks Therapeutics Trading Down 5.4 %

NASDAQ SWTX opened at $36.99 on Tuesday. SpringWorks Therapeutics, Inc. has a 1-year low of $28.21 and a 1-year high of $62.00. The firm’s fifty day simple moving average is $48.73 and its 200-day simple moving average is $40.01. The company has a market capitalization of $2.77 billion, a PE ratio of -10.63 and a beta of 0.79.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The firm had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. As a group, analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.